Ball D - Search Results

1

Single-Fraction vs Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastases (SAFRON II): The Trans Tasman Radiation Oncology Group 13.01 Phase 2 Randomized Clinical Trial.

Siva S, Bressel M, Mai T, Le H, Vinod S, de Silva H, Macdonald S, Skala M, Hardcastle N, Rezo A, Pryor D, Gill S, Higgs B, Wagenfuehr K, Montgomery R, Awad R, Chesson B, Eade T, Wong W, Sasso G, De Abreu Lourenco R, Kron T, Ball D, Neeson P; Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung (SAFRON) II Study Investigators. Siva S, et al. Among authors: ball d. JAMA Oncol. 2021 Oct 1;7(10):1476-1485. doi: 10.1001/jamaoncol.2021.2939. JAMA Oncol. 2021. PMID: 34455431 Free PMC article. Clinical Trial.

2

A phase III study of accelerated radiotherapy with and without carboplatin in nonsmall cell lung cancer: an interim toxicity analysis of the first 100 patients.

Ball D, Bishop J, Smith J, Crennan E, O'Brien P, Davis S, Ryan G, Joseph D, Walker Q. Ball D, et al. Int J Radiat Oncol Biol Phys. 1995 Jan 15;31(2):267-72. doi: 10.1016/0360-3016(94)E0021-B. Int J Radiat Oncol Biol Phys. 1995. PMID: 7836079 Clinical Trial.

3

A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial.

Ball D, Bishop J, Smith J, O'Brien P, Davis S, Ryan G, Olver I, Toner G, Walker Q, Joseph D. Ball D, et al. Radiother Oncol. 1999 Aug;52(2):129-36. doi: 10.1016/s0167-8140(99)00093-6. Radiother Oncol. 1999. PMID: 10577698 Clinical Trial.

4

Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure.

Mac Manus MP, Wada M, Matthews JP, Ball DL. Mac Manus MP, et al. Among authors: ball dl. Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):63-9. doi: 10.1016/s0360-3016(99)00357-0. Int J Radiat Oncol Biol Phys. 2000. PMID: 10656374

5

Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.

Kalff V, Hicks RJ, MacManus MP, Binns DS, McKenzie AF, Ware RE, Hogg A, Ball DL. Kalff V, et al. Among authors: ball dl. J Clin Oncol. 2001 Jan 1;19(1):111-8. doi: 10.1200/JCO.2001.19.1.111. J Clin Oncol. 2001. PMID: 11134203

6

Combined modality treatment using concurrent radiotherapy and pharmacologically-guided carboplatin for inoperable and incompletely resected non-small cell lung cancer.

Grossi M, Millward M, Fisher R, Porceddu S, Mac Manus M, Ryan G, Wirth A, Ball D. Grossi M, et al. Among authors: ball d. Lung Cancer. 2001 Jan;31(1):73-82. doi: 10.1016/s0169-5002(00)00164-1. Lung Cancer. 2001. PMID: 11162869

7

High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy.

MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, Ware RE, Ball DL. MacManus MP, et al. Among authors: ball dl. Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):287-93. doi: 10.1016/s0360-3016(01)01477-8. Int J Radiat Oncol Biol Phys. 2001. PMID: 11380213 Clinical Trial.

8

F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.

Mac Manus MP, Hicks RJ, Ball DL, Kalff V, Matthews JP, Salminen E, Khaw P, Wirth A, Rischin D, McKenzie A. Mac Manus MP, et al. Among authors: ball dl. Cancer. 2001 Aug 15;92(4):886-95. doi: 10.1002/1097-0142(20010815)92:4<886::aid-cncr1397>3.0.co;2-v. Cancer. 2001. PMID: 11550162

9

Positron emission tomography in pulmonary masses where tissue diagnosis is unhelpful or not possible.

Pitman AG, Hicks RJ, Kalff V, Binns DS, Ware RE, McKenzie AF, Ball DL, MacManus MP. Pitman AG, et al. Among authors: ball dl. Med J Aust. 2001 Sep 17;175(6):303-7. doi: 10.5694/j.1326-5377.2001.tb143587.x. Med J Aust. 2001. PMID: 11665943

10

(18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.

Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF, Matthews JP, Ball DL. Hicks RJ, et al. Among authors: ball dl. J Nucl Med. 2001 Nov;42(11):1596-604. J Nucl Med. 2001. PMID: 11696627 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,152 results

Search Page

Filters